

**From:** [Charles Price, MD](#)  
**To:** [Pharmacy Services](#)  
**Subject:** Atypical Caplyta for inclusion on PDL 12-9-21  
**Date:** Wednesday, November 17, 2021 12:45:05 PM

---

November 17, 2021

Dear Silver State Script Board,

I am writing you to show my support for the atypical antipsychotic, Caplyta, to be included on the Nevada Medicaid PDL. In my clinical experience there are a number of features with Caplyta that I have found helpful for my patients. The drug is in the rare category of having placebo like changes in metabolic, EPS, prolactin, and even weight change. The MOA also gives us clinicians the ability to reach for something that has slightly different receptor activity. Lastly, I believe formularies should be as open as possible to allow physicians a wide variety of medicines with which to treat their patients. Schizophrenia is a very heterogeneous disease and the inclusion of Caplyta on the PDL would offer those still suffering an additional treatment choice.

Thank you very much for your time and consideration. If you have any further questions please feel free to reach out.

Warm Regards,

Dr. Charles Price

313 Flint St.

Reno, NV. 89501

775-324-5466